Roche signs inclacumab deal with GBT
Roche has sold off rights to inclacumab to Global Blood Therapeutics, which intends to develop the treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD).
Read More
Tag: vaso-occlusive crises
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
